Financials

News Ideas Discussions Technicals Forecast Seasonals

ALGEN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. Its technologies include CRISPR/Cas9, homologous recombination (HR), site-specific recombination (SSR), internal ribosome entry sites (IRES), and tetracycline (TET). The company was founded by Alexandre Fraichard and Gilles de Poncins on March 1, 1999, and is headquartered in Lyon, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ALGEN has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company